BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for cynata therapeutics

Cynata Introduces a Scalable Mesenchymal Stem Cell (MSC) Manufacturing Platform

By

Cynata TherapeuticsCynata Therapeutics is a regenerative medicine company,  listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).

UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007.

Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of human embryonic stem cell (hESC) derivation.  [Read more…]

Cynata Therapeutics and Harvard to Target Cancer with Toxin-Secreting Stem Cells

By

Cynata’s Stem Cell Manufacturing Platform to Allow for Scalability of Harvard’s Modified Stem Cells

While methods for treating cancer have improved over the past decade, there remain limited techniques for addressing aggressive cancers, including those that cannot be surgically removed due to location or type. Cancers such as glioblastoma, the most common and aggressive type of brain tumour in adult humans, continue to produce high fatality rates. In addition, chemotherapy remains a widespread technique for killing or stopping cancer progression,  despite its extremely harmful side effects. For this reason, cell therapies are now being explored for their potential to act as targeted cancer killing agents. [Read more…]

3 Bullet Thursday – Week of October 15, 2015

By

Stay alert to the latest and greatest on stem cells.  Enjoy this week’s “3 Bullet Thursday,” a weekly post that we do to update you on interesting and important events within the world of stem cells.

(1) The world’s first clinical trial to inject stem cells into the womb was announced. The trial, starting in January 2016, will be headed by Sweden’s Karolinska Institute and the UK’s Great Ormond Street Hospital. It will seek to address osteogenesis imperfecta, or “brittle bone disease,” by using injected stem cells to correct errors within the fetal DNA. [Read more…]

BioInformant's World-Class Clients